FDA Approval Summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.
暂无分享，去创建一个
A. Fotenos | R. Pazdur | H. Gittleman | L. Amiri-Kordestani | Shenghui Tang | A. Ibrahim | P. Kluetz | Tiffany K Ricks | D. Suzman | W. Pierce | M. Fiero | Wei Chen | S. Agrawal | Sriram Subramaniam | Jaleh Fallah | C. John | Min Wang | Gang Niu | Kelly Chiang